Loading...
Market
Next major FDA regulatory action on Trodelvy by end of 2025?
2
Resolution / Starting Odds
Approval for a new indication • 25%
Rejection of a new application • 25%
Withdrawal of another indication • 25%
No major action • 25%
FDA announcements and Gilead Sciences press releases
Story
Gilead Sciences Withdraws Trodelvy Approval for Bladder Cancer
Oct 18, 2024, 04:01 PM
Gilead Sciences announced on Friday that it will voluntarily withdraw the U.S. accelerated approval for its drug Trodelvy (sacituzumab govitecan-hziy) for the treatment of adult patients with locally advanced or metastatic urothelial cancer, specifically in previously treated bladder cancer. The decision follows the results of the TROPiCS-04 study, which failed to meet its primary endpoint of overall survival. Despite this withdrawal, other indications for Trodelvy remain unaffected. The withdrawal comes after consultation with the FDA.
View original story
Similar markets
Full Approval • 25%
Accelerated Approval • 25%
Conditional Approval • 25%
No Approval • 25%
European Union • 25%
Japan • 25%
Canada • 25%
Other • 25%
0-5 trials • 25%
6-10 trials • 25%
11-15 trials • 25%
More than 15 trials • 25%
Yes • 50%
No • 50%
Leading • 25%
Second • 25%
Third • 25%
Lower • 25%
Significant Improvement • 25%
Moderate Improvement • 25%
No Change • 25%
Worse Outcomes • 25%